NCT03716427 is a Phase 1 clinical trial of CT1812 in Healthy Volunteers, sponsored by Cognition Therapeutics.

Who is sponsoring NCT03716427?

NCT03716427 is sponsored by Cognition Therapeutics.

What drugs are being tested in NCT03716427?

Interventions in NCT03716427: CT1812, tolbutamide, dextromethorphan, Omeprazole, midazolam.

What condition does NCT03716427 study?

NCT03716427 studies Healthy Volunteers.

Is NCT03716427 still recruiting?

NCT03716427 is currently completed. Last updated 23 October 2018.

Last reviewed 2018-10-23 · How we verify

NCT03716427

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug Interaction Study of CT1812 in Healthy Volunteers

Completed Phase 1 Last updated 23 October 2018

What this trial tests

Phase 1 trial testing CT1812 in Healthy Volunteers in 16 participants. Completed in 15 February 2017.

Timeline

10 November 2016

Primary endpoint
27 December 2016

15 February 2017

Quick facts

Lead sponsor	Cognition Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	10 November 2016
Primary completion	27 December 2016
Estimated completion	15 February 2017
Sites	1 location across United States

Drugs / interventions tested

CT1812 — full drug profile →
tolbutamide (TOLBUTAMIDE) — full drug profile →
dextromethorphan — full drug profile →
Omeprazole (omeprazole) — full drug profile →
midazolam (midazolam) — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Cognition Therapeutics — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is Phase 1, single-center, open-label, single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole).

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders.
Malar DS, Thitilertdecha P, Ruckvongacheep KS, Brimson S, et al · · 2023 · cited 39× · PMID 37166702 · DOI 10.1007/s40263-023-01007-6
The Sigma Receptors in Alzheimer's Disease: New Potential Targets for Diagnosis and Therapy.
Wang T, Jia H. · · 2023 · cited 19× · PMID 37569401 · DOI 10.3390/ijms241512025
Advancements in Pharmacological Treatment of Alzheimer's Disease: The Advent of Disease-Modifying Therapies (DMTs).
Wang Q, Chen S, Wang J, Shang H, et al · · 2024 · cited 7× · PMID 39452004 · DOI 10.3390/brainsci14100990
The Allosteric Antagonist of the Sigma-2 Receptors-Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer's Disease: A Scoping Systematic Review.
Rasheed A, Zaheer AB, Munawwar A, Sarfraz Z, et al · · 2022 · cited 7× · PMID 36675950 · DOI 10.3390/life13010001
A Review of the Clinical Progress of CT1812, a Novel Sigma-2 Receptor Antagonist for the Treatment of Alzheimer's Disease.
Steinfield SR, Stenn DF, Chen H, Kalisch BE. · · 2025 · cited 4× · PMID 40430478 · DOI 10.3390/ph18050659
Advances in synaptic PET imaging and intervention with synapse-targeted small-molecular drugs for dementia diagnosis and therapy.
Lu X, Ji B, Huang G, Ding H. · · 2025 · cited 1× · PMID 40166112 · DOI 10.1016/j.fmre.2024.04.013
Sigma receptors and mitochondria-associated ER membranes are converging therapeutic targets for Alzheimer's disease.
Lotlikar MS, Zellmer JC, Bhattacharyya R. · · 2025 · PMID 41488323 · DOI 10.3389/fnins.2025.1733659

Verify or expand the search:

Other trials of CT1812

Trials testing the same drug.

NCT05225415 — Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy B · Phase 2 · completed
NCT05248672 — Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers · Phase 1 · completed
NCT04735536 — Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG · Phase 2 · completed
NCT03507790 — A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. · Phase 2 · completed
NCT03522129 — Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to · Phase 1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Cognition Therapeutics trials

Trials by the same sponsor.

NCT05893537 — Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry A · Phase 2 · terminated
NCT05225415 — Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy B · Phase 2 · completed
NCT05248672 — Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers · Phase 1 · completed
NCT05225389 — Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects · Phase 1 · completed
NCT04735536 — Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03716427 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cognition Therapeutics
Last refreshed: 23 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03716427.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing